secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-08-13T20:33:34+00:00
Accession:  0001193125-26-349353
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera prices $200M public offering of common shares and pre-funded warrants
-------------------------------------------------------------------------------

- 17,435,897 common shares at $9.75/share and 3,076,926 pre-funded warrants at $9.74999 each.
- Gross proceeds ~$200M; net proceeds ~$187M after underwriting discounts and estimated expenses.
- Proceeds to fund internal pipeline including lead program ABCL635, plus working capital and general corporate purposes.
- Offering expected to close Aug 14, 2026; Jefferies, J.P. Morgan, Cantor, UBS, BMO act as joint book-runners.
- Company and insiders subject to 60-day lock-up on share sales following the underwriting agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000119312526349353/0001193125-26-349353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000119312526349353/d20959d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer